Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 13/20 | 0.51 |
| ▸ | MMP1 | P03956 | 13/20 | 0.51 |
| ▸ | MMP3 | P08254 | 12/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MMP7 | P09237 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7761465 | 0.92 | MMP1 (0.43) | MMP2MMP1MMP3NPC1RAB9A | |
| SCHEMBL7763658 | 0.92 | MMP2 (0.47) | MMP2MMP1MMP3NPC1RAB9A | |
| Methyl Benzoate SCHEMBL7763173 | 0.73 | MMP2 (0.48) | MMP2MMP1MMP3 | |
| SCHEMBL7758470 | 0.71 | MMP2 (0.75) | MMP2MMP1MMP3 | |
| SCHEMBL7761478 | 0.70 | MAPT (0.42) | MMP2MMP3NPC1RAB9A | |
| SCHEMBL7765121 | 0.69 | RAB9A (0.45) | NPC1RAB9A | |
| SCHEMBL7761449 | 0.69 | MMP2 (0.83) | MMP2MMP1MMP3 | |
| SCHEMBL7758727 | 0.69 | MMP3 (0.47) | MMP2MMP1MMP3MMP7NPC1 | |
| SCHEMBL29134529 | 0.69 | RAB9A (0.64) | NPC1RAB9A | |
| SCHEMBL29134528 | 0.69 | RAB9A (0.64) | NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |